LCMD-L302P-UCL01C2
UCLi006-A
General
Cell Line |
|
hPSCreg Name | UCLi006-A |
Alternative name(s) |
LCMD-L302P-UCL01C2
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines | |
Last update | 18th October 2019 |
User feedback | |
Provider |
|
Generator | University College London (UCL) |
Distributors | |
Derivation country | United Kingdom |
External Databases |
|
BioSamples | SAMEA104130970 |
Cellosaurus | CVCL_VF11 |
CLO | CLO_0101660 |
Wikidata | Q54989674 |
General Information |
|
Projects | |
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: allowed
|
Donor Information
General Donor Information |
|
Sex | male |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
BioSamples | SAMEA104130971 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
Provide contact information of the holder of the original Donor Information Sheet: | Jean-Marie.CUISSET@CHRU-LILLE.FR |
Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
Is there other documentation provided to the donor for consenting purposes? | No |
Confirm that consent was obtained by a qualified professional | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent expressly prevent the derivation of pluripotent stem cells? | No |
Does consent pertain to a specific research project? | Yes |
Details on restriction to research project | Use in research for muscular dystrophies |
Does consent permit unforeseen future research, without further consent? | Yes |
Does consent expressly prevent development of commercial products? | No |
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
How may genetic information associated with the cell line be accessed? | No information |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | Yes |
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | |
Approval number | |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | |
Approval number | |
Do you have obligations to third parties in regard to the use of the cell line? | Yes |
Please describe: | Use in research for muscular dystrophies |
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
fibroblast of dermis |
Source cell origin |
zone of skinAny portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis.
|
Reprogramming method |
|
Vector type | Integrating |
Vector | Virus (Lentivirus) |
Genes | |
Is the used vector excisable? |
No |
Absence of reprogramming vector(s)? |
No |
Reprogramming vectors silenced? |
Yes |
Methods used |
Immunostaining, RT-PCR
|
Vector map | |
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions
Surface coating | Vitronectin |
Feeder cells |
No |
Passage method |
Enzyme-free cell dissociation
EDTA
|
Medium |
TeSR™ E8™
|
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
NANOG |
Yes |
|||||
SOX2 |
Yes |
|||||
POU5F1 (OCT-4) |
Yes |
|||||
Alkaline Phosphatase |
Yes |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.